drugset / Trial / NCT00783081

Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication

NCT00783081

Phase 2 Completed 387 enrolled Kowa Research Institute, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of K-134 for the treatment of intermittent claudication.

Timeline

Start
2008-11
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cilostazol Small molecule 100 mg
Subject K-134 Small molecule 25 mg
Subject K-134 Small molecule 50 mg
Subject K-134 Small molecule 100 mg